Edition:
United States

iKang Healthcare Group Inc (KANG.OQ)

KANG.OQ on NASDAQ Stock Exchange Global Select Market

14.57USD
3:59pm EST
Change (% chg)

$-0.05 (-0.34%)
Prev Close
$14.62
Open
$14.65
Day's High
$14.65
Day's Low
$14.43
Volume
55,331
Avg. Vol
63,029
52-wk High
$18.41
52-wk Low
$11.70

Chart for

About

iKang Healthcare Group, Inc. provides preventive healthcare solutions, including a range of medical examinations services and value-added services, including disease screening, dental services and other services in China. The Company's segments include medical examinations and other medical services, and dental services. The... (more)
No analyst recommendations are available for .

Overall

Beta: 0.26
Market Cap(Mil.): $941.19
Shares Outstanding(Mil.): 68.50
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 28.77 16.44
EPS (TTM): -- -- --
ROI: -- 6.39 10.62
ROE: -- 10.09 14.20

BRIEF-Ikang Announces Q2 Results

* IKANG ANNOUNCES UNAUDITED FINANCIAL RESULTS FOR THE FISCAL SECOND QUARTER ENDED SEPTEMBER 30, 2017

5:08pm EST

BRIEF-Ikang Healthcare Group Extends Shareholder Rights Plan

* IKANG HEALTHCARE GROUP, INC. EXTENDS SHAREHOLDER RIGHTS PLAN

Nov 29 2017

BRIEF-Fosun International reports 5.02 percent passive stake in iKang Healthcare

* Fosun International Limited reports 5.02 percent passive stake in iKang Healthcare Group Inc ‍​as of September 20 - sec filing Source text : http://bit.ly/2yNNbQ2 Further company coverage:

Sep 29 2017

BRIEF-IKANG QTRLY NON-GAAP INCOME PER ADS ATTRIBUTABLE TO COMMON SHAREHOLDERS WERE $0.06

* IKANG ANNOUNCES UNAUDITED FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED JUNE 30, 2017

Sep 14 2017

BRIEF-iKang Group enters into partnership with Baheal Intelligent Technology

* iKang Group announces partnership to establish ibm watson oncology centers in china

Jul 28 2017

BRIEF-iKang's Q4 revenue rose 13.9 percent

* iKang announces unaudited financial results for the fiscal fourth quarter and the fiscal year 2016 ended March 31, 2017

Jun 22 2017

Earnings vs. Estimates